Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection

Diletta, Stea Emma; Pronzo, Virginia; Francesco, Pesce; Fiorentino, Marco; Adele, Mitrotti; Vincenzo, Di Leo; Cosma, Cortese; Annalisa, Casanova; Sebastiano, Nestola; Flavia, Capaccio; Gesualdo, Loreto

doi:10.29328/journal.jcn.1001088

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… CPT considerably raises the Abs content in serious and critical in patients. Emma Diletta Stea et al 143 CPT in a SARS-CoV-2-infected HUS patient (Case Presentation) October 2020 Polyclinic of Bari Female Caucasian, 52 years old HIP CPAP Enoxaparin, Dexamethasone, Azithromycin, Ceftriaxone, Daptomycin Blood gas measurement after the second plasma administration showed an improvement in the PO 2 /FiO 2 ratio. Using the HIP as a sort of rescue therapy may be beneficial for patients with a history of HUS and mild to severe SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula¹,

Tuji²,

Gudeta³

et al. 2023

JBM

View full text Add to dashboard Cite

Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.

show abstract